TRANSFORM:
Maintained graft protection with minimized toxicities using Certican® + reduced CNI
TRANSFORM Trial
A large trial in de novo renal transplant looked at how Certican® with reduced CNI compares against standard therapy in kidney transplant patients1
Prospective open‐label trial
n=2,037 de novo renal transplant recipients*
Stabilize eGFR1
eGFR < 50 mL/min per 1.73 m2 occured similarly in both groups
Mean eGFR:
52.6 vs. 54.9 mL/min per 1.73 m2 in the EVR + rCNI vs MPA + sCNI arm, respectively (P = 0.028)1
Low incidence of viral infection1
Compared to standard therapy, Certican® + rCNI had LOWER incidence of:
Safety outcomes beyond graft function1
Most AEs occurred in the first 12 months, and none of the AEs had an incidence of ≥10% in either arm from months 12 to 24.1
*Full analysis patient population
Abbreviations:
CNI, Calcineurin inhibitors; EVR, everolimus; MPA, Mycophenolate; rCNI, reduced-exposure calcineurin inhibitors; sCNI, standard -exposure calcineurin inhibitors; tBPAR, Treated biopsy‐ proven acute rejection; eGFR, estimated glomerular filtration rate; CMV, cytomegalovirus; BKV, BK virus; 95% CI, 95% confidence interval; AE, adverse effects
Reference:
1. Berger SP, et al. Am J Transplant. 2019;19(11):3018-3034.
20 Pasir Panjang Road #10-25/28 Mapletree Business City (West Tower) Singapore 117439
Phone: +65 6722 6010
This content is not for local distribution. This should be modified to accommodate local guidance before local distribution.
FOR HEALTHCARE PROFESSIONALS ONLY
Please visit https://www.novartis.com/sg-en/product-list/certican to access or download the Package Insert.
Alternatively, please scan this code for more Information about this medicine.
FA-11458344_2027Jul22